A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pirfenidone (ESBRIET)

indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

First FDA approval2017-01-11
Generic availableYes · 14 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$259.4M in CY2024 Part D spend100K claims · 19K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.52/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.52
Across all dosage forms in distribution.
Highest NADAC
$1.52
Range is tight.
Plans with PA
1155 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Pirfenidone used for?

indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Is there a generic for Pirfenidone?

Yes. 34 ANDAs filed at FDA, 14 generic manufacturers currently shipping.

How much does my plan pay for Pirfenidone?

Across 329 Part D plans, Pirfenidone averages $1.52/unit (NADAC). Lowest available: $1.52/unit. Highest in distribution: $1.52/unit.

Is Pirfenidone on the FDA shortage list?

No. Pirfenidone is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Pyridone1 alternative in D1
01
Pirfenidone Capsule,
Pyridone
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.